Azithromycin
Brand names: Zithromax
Azithromycin is a macrolide antibiotic with a long tissue half-life, used for respiratory, skin and soft-tissue, and certain sexually transmitted and atypical infections, and prophylactically in some chronic respiratory conditions.
Adult dose
Paediatric dose
Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.
UK SPC, paediatric patients aged 6 months and older weighing <45 kg, single daily dose. Acute bacterial sinusitis / community-acquired pneumonia / acute bacterial skin and skin structure infections: 10 mg/kg/day for 3 days, or 10 mg/kg on day 1 then 5 mg/kg/day on days 2–5. Acute bacterial otitis media: single dose of 30 mg/kg, or 10 mg/kg/day for 3 days, or 10 mg/kg day 1 then 5 mg/kg/day days 2–5. Acute streptococcal tonsillitis and pharyngitis: 20 mg/kg/day for 3 days, or 12 mg/kg/day for 5 days.
Contraindications
- Hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic, or any excipient
- History of cholestatic jaundice/hepatic dysfunction associated with prior azithromycin use (US label)
Side effects
- Diarrhoea
- Nausea
- Vomiting
- Abdominal pain
- Headache
Interactions
- QT-prolonging drugs — increased risk of ventricular arrhythmia/torsades de pointes
- Warfarin/oral anticoagulants — may potentiate effect; monitor prothrombin time
- Nelfinavir — increased azithromycin concentrations; monitor for adverse reactions
Clinical monograph
How it works
It binds the bacterial 50S ribosomal subunit and inhibits protein synthesis by blocking translocation, giving bacteriostatic and, at higher concentrations, bactericidal activity against susceptible organisms.
Prescribing in practice
- Azithromycin can prolong the QT interval, so it should be used with caution in patients with cardiac risk factors, electrolyte disturbance, or concomitant QT-prolonging drugs.
- It carries a recognised risk of hepatotoxicity and should be reviewed if signs of liver dysfunction develop.
- Long courses for respiratory prophylaxis warrant consideration of macrolide resistance and hearing assessment.
Monitoring
Monitor liver function and, where there is cardiac risk or prolonged use, ECG, electrolytes and hearing as appropriate.
Counselling the patient
- Complete the prescribed course even if you feel better.
- Report palpitations, fainting, or yellowing of the skin or eyes.
- Tell your clinician about any heart-rhythm problems or other medicines you take.
Evidence & guidelines
Azithromycin features in UK antimicrobial guidance for various infections, with the MHRA having highlighted its association with QT-interval prolongation.
Reference: BASHH STI Guidelines; RECOVERY Trial (Horby et al, NEJM 2021); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Centor / McIsaac Score for Strep Pharyngitis · Throat
- FeverPAIN Score for Strep Throat · Throat
- Jarisch-Herxheimer Reaction Severity Assessment · Treatment Reactions
- PID Severity (CDC Diagnostic Criteria) · Gynaecological Infections
- Gustilo-Anderson Classification (Open Fractures) · Fracture Classification
- DRIP Score for Drug-Resistant Pneumonia · Pneumonia